5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow Ciliary Neurotrophic Factor: new trials by email Literature Review of Ciliary Neurotrophic Factor trials Research Report on Ciliary Neurotrophic Factor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) Ciliary neurotrophic factor (CNTF), Surgery - MacTel (Macular Telangiectasia) Type 2 | Phase 2 | Completed | Neurotech Pharmaceuticals | 70 | 2017-05-12 | 2025-05-09 |
| A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel Ciliary neurotrophic factor (CNTF), Sham procedure, NT-501 Implant - Macular Telangiectasia Type 2 | Phase 2 | Completed | Neurotech Pharmaceuticals | 67 | 2014-04-01 | 2018-09-12 |
| Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa NT-501, Sham - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Completed | Neurotech Pharmaceuticals | 22 | 2012-01-01 | 2023-02-14 |
| A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa NT-501 - Retinitis Pigmentosa | Phase 2 | Completed | Neurotech Pharmaceuticals | 73 | 2007-01-22 | 2025-05-01 |
| A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa Low Dose NT-501, High Dose NT-501 - Retinitis Pigmentosa | Phase 2 | Completed | Neurotech Pharmaceuticals | 67 | 2007-01-08 | 2024-08-13 |
Retinitis Pigmentosa (3) · Eye Diseases (2) · Retinal Diseases (2) · Usher Syndromes (1)
United States (5) · Australia (2)
David Birch, MD (1) · David Birch, MD, PhD (1) · Jacque Duncan, MD (1) · Thomas Aaberg, Jr, MD (1)